dansylsarcosine has been researched along with Diabetic Nephropathies in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anraku, M; Chuang, VT; Kawai, K; Komatsu, T; Maruyama, T; Otagiri, M; Seo, H; Taguchi, K; Tanaka, R; Urata, Y; Yamasaki, K | 1 |
1 other study(ies) available for dansylsarcosine and Diabetic Nephropathies
| Article | Year |
|---|---|
Cross-linked human serum albumin dimer has the potential for use as a plasma-retaining agent for the fatty acid-conjugated antidiabetic drugs.
Topics: Animals; Binding Sites; Dansyl Compounds; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dimerization; Drug Carriers; Fatty Acids; Fluorescent Dyes; Half-Life; Humans; Hypoglycemic Agents; Male; Maleimides; Permeability; Plasma; Protein Binding; Rats; Rats, Sprague-Dawley; Sarcosine; Serum Albumin; Warfarin | 2015 |